Elsevier acquires Edra S.p.A.

Edra S.p.A. provides e-pharma promotional services and is Continual Medical Education provider

Milan, Italy – 22 January 2008 – Elsevier, the world’s leading publisher of science and health information, announced today that it has acquired Edra S.p.A., an online publishing company in the healthcare field. Together, Elsevier and Edra will be able to provide professional and promotional support to pharmaceutical companies by combining Elsevier’s content and services with Edra’s electronic capabilities and online delivery channel. An important tool is Medikey, the largest online medical and healthcare professional community in Italy.

Elsevier, based in Milan, is the market leading provider of scientific and medical content and services, in the form of books, journals, drug databases and pharmaceutical marketing support.

Edra S.p.A., also based in Milan, provides e-pharma promotional services and is a Continual Medical Education provider certified by the Italian Ministry of Health and the region of Lombardy, both for residential and distance learning. The company was founded in 1986 by Vincenzo Coluccia, who holds majority ownership in Edra and is Managing Director.

Edra is well known for Medikey, a broad medical community of 200,000 Italian doctors, 37,000 pharmacists, 40,000 healthcare professionals (biologists nurses, etc), 70,000 policy and decision makers (national and regional ones), and Azfarma, a community of more than 15,000 pharma and medical device managers.

Edra publishes important online magazines including Doctornews33, Dermatologia33 and Cardiologia33 for doctors, Farmacista33 for pharmacists and Pharmamarketing to pharma managers. Edra also maintains the portals www.dica33.it (the leading Italian consumer health portal) www.doctor33.it, (the leading medical doctors portal), and www.pharmamarketing.it (for pharmaceutical company professionals).

Vincenzo Coluccia, Managing Director of Edra, comments: “We see wonderful opportunities to serve Edra clients even better by giving them access to the superior Elsevier Masson content and services. I look forward to contribute to the development of the possibilities that will emerge”.

Wubbo Tempel, Managing Director of Elsevier Masson Italy, says: “This is a very important acquisition for Elsevier as there will be no other company in Italy able to deliver personalized content service directly to health care professionals in the way we will be able to”.

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.

Media Contact:
Shira Tabachnikoff
+31 20 485 2736